Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 2 Laboratory findings of patients with macrophage activation syndrome

From: Tocilizumab modifies clinical and laboratory features of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis

 TocilizumabHistoric cohort
Full-blown (n = 2)Possible (n = 10)All (n = 12)Full-blown (n = 10)Possible (n = 8)All (n = 18)
Ferritin (ng/ml)12,645587**664***11,0358518**9235***
4155–21,135402–2330410–37856585–32,6443390–11,8335559–18,710
Platelets (× 104/mm3)12.411.7****11.7***14.521.9****18.9***
7.6–17.27.7–13.17.7–13.312.1–18.520.2–32.213.3–21.8
AST (IU/l)6661191612966389
382–94961–29063–43878–68153–9261–425
TG (mg/dl)362108*113*279148*214*
149–57491–13294–150192–298141–213143–285
Fibrinogen (mg/dl)116118****118****281319****294****
80–152102–17297–163217–292302–482240–362
CRP (mg/dl)3.10.03****0.03****7.59.6****7.6****
0.0–6.10.0–0.60.0–6.13.3–12.94.7–15.13.7–13.6
  1. Median values and IQR were shown. * = p < 0.05; ** = p < 0.01; *** = p < 0.001; **** = p < 0.0001; AST Aspartic aminotransferase, TG Triglyceride, CRP C reactive protein